SLC22A1 and type 2 diabetes mellitus: We hypothesize that developmental defects of the liver and/or the endocrine pancreas, indicated by decreased in vitro DE and PP formation after ablation of SLC22A1, might contribute to this adverse response to metformin treatment in T2D patients carrying reduced-function SLC22A1 variants.